Clovis Oncology announces availability and reimbursement for Rubraca (rucaparib) tablets for women with relapsed ovarian cancer in Spain

Clovis Oncology

2 March 2020 - Rucaparib now available in multiple countries across Europe.

Clovis Oncology today announced that Rubraca (rucaparib) is now available and reimbursed in Spain following the Spanish Interministerial Commission on Prices of Medicines and Health Products approval of rucaparib for reimbursement. 

Rucaparib is now available as an option for monotherapy maintenance treatment for adults with relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy.

Read Clovis Oncology press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Market access , Spain